NEW YORK, July 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

India Biotechnology in India Industry

http://www.reportlinker.com/p0553099/India-Biotechnology-in-India-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Disc

This report analyzes the market for Biotechnology in India in US$ million by the following Key Sectors: Bio-Pharmaceuticals, Bio-Agriculture, Bio-Industrial, Bioinformatics, and Bio-Services. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for this market. The report profiles 102 companies including many key and niche players such as Advanced Enzymes Technologies Ltd., Ajeet Seeds Ltd., Anthem BioSciences Pvt. Ltd., Bharat Biotech International Limited, Bharat Serums and Vaccines Ltd., Biocon Limited, Syngene International Limited, Dr. Reddy's Laboratories Ltd., Ecron Acunova, Eli Lilly and Company (India) Pvt. Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Indian Immunologicals Ltd., Jubilant Life Sciences Limited, Krishidhan Seeds Private Limited, Lambda Therapeutic Research Ltd., Mahyco, Max Neeman, Monsanto, Novo Nordisk India Pvt. Ltd., Novozymes South Asia Pvt. Ltd., Nuziveedu Seeds Pvt. Ltd., Ocimum Biosolutions Ltd., Panacea Biotec Ltd., Piramal Healthcare Limited, Quintiles India, Rasi Seeds (P) Ltd., Reliance Life Sciences, Serum Institute of India Ltd., Shantha Biotechnics Limited, SIRO Clinpharm, Strand Life Sciences, Veeda Clinical Research Limited, and Vimta Labs Limited. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definition and Scope of Study I-3 Bio-Pharmaceuticals I-3 Bio-Agriculture I-3 Bio-Industrial I-3 Bioinformatics I-3 Bio-Services I-3

II. AN INDIAN MARKET REPORT

1. OUTLOOK II-1 Recession and Foreign Exchange Rate Decelerate Industry Growth II-1 Industry Emerges Strong Following Recession II-2 Brighter Prospects Ahead for the Indian Biotech Industry II-2

2. INDUSTRY OVERVIEW II-3 SWOT Analysis II-3 Diversity - Key Strength for the Industry II-4 Major Sectors in the Indian Biotechnology Industry II-4 Government Support for Biotech Innovation - A Boost for the Industry II-5 Challenges Ahead II-5 Concerted Efforts are On to Find a Way Out II-6 Major Industry-Specific Advantages of the Indian Biopharma Sector II-6 Competition II-7

Table 1: Leading Biotech Companies in India by Revenues: 2009-10 (includes corresponding Graph/Chart) II-7

Table 2: Leading Domestic Biotech Companies in India by Revenues: 2009-10 (includes corresponding Graph/Chart) II-8 Exports - A Major Market for Indian Biotech Industry II-8

Read more from the original source:
India Biotechnology in India Industry

MENLO PARK, Calif.--(BUSINESS WIRE)--

Two papers in Nature Biotechnology, both published online on July 1, 2012 highlight the unique value for de novo genome assembly provided by the PacBioRS High Resolution Genetic Analyzer from Pacific Biosciences of California, Inc. (PACB).

Due to the inherent limitations of commonly used short-read sequencing technologies, the genomes of very few species have been completely sequenced, or finished. PacBios single molecule, real-time (SMRT) technology offers very long reads that reduce the number of contiguous sequences, or contigs, to simplify and improve genome assembly. These multi-kilobase reads allow scientists to sequence through long repeat regions and to identify structural variation, which are common in genomes but not possible to resolve completely with short-read platforms. As a result, PacBio long reads can lead to final assemblies that matchand in some cases even exceedthe quality that previously counted as finished, approaching the gold standard of a perfect genome.

In the publication from Koren et al., titled Hybrid error correction and de novo assembly of single-molecule sequencing reads, the authors demonstrate a new pipeline for assembly of the parrot genome. Using PacBio long reads in combination with high-accuracy short reads and an updated version of Celera Assembler, they assembled for the first time regulatory regions of genes involved in vocal learning circuits. The hybrid reads represent the most complete assembled bird genome now available.

"Repetitive regions are the biggest impediment to all assembly algorithms and sequencing technologies as they introduce ambiguity in the reconstruction of the genome, said Sergey Koren, Ph.D., Scientist of Bioinformatics at the National Biodefense Analysis and Countermeasures Center. Using the long reads we have access to longer sequences, which increases the probability of spanning a repeat and leads to better assemblies at lower depths than short reads.

A separate publication from Bashir et al., titled A hybrid approach for the automated finishing of bacterial genomes, describes combining contigs from second-generation sequencing technologies with PacBio sequence data for the cholera strain responsible for the 2010 Haitian outbreak. The authors show that their hybrid assembly resolved complex regions with several repeats and suggest that the approach offers a solution for rapid identification and assembly of full microbial genomes.

The publication of these two studies is evidence of how our long-read technology is emerging as the gold standard for finishing genome assemblies and identifying, annotating and deciphering genomic structure, said Mike Hunkapiller, President and CEO at Pacific Biosciences. Moreover, investigators are finding creative ways to take advantage of the unique benefits provided by our SMRT sequencing and enabling scientific applications that are simply not possible with short-read sequencing platforms.

The Nature Biotechnology publication details are as follows:

For more information on de novo genome assembly with the PacBioRS, please visit our website at http://www.pacb.com/denovo.

About Pacific Biosciences

See the original post:
Nature Biotechnology Publications Showcase Value of PacBio RS in De Novo Genome Assembly

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) today applauded the Department of Defenses announced public-private partnership opportunity to support an integrated domestic advanced drop-in biofuel biorefinery. The funding opportunity is designed to share the cost of establishing one or more first-of-a-kind biorefineries and feedstock supply chains to provide the U.S. military with already certified blends of biofuels.

Brent Erickson, executive vice president of BIOs Industrial & Environmental Section, stated, The domestic advanced biofuel industry can play a huge part in promoting energy security, which is critical for military readiness and national security. Ensuring the reliability and affordability of fuel supplies through diversification to advanced drop-in alternative fuels is essential to sustain the U.S. militarys readiness, since oil price volatility has already negatively impacted military readiness. This year alone, the $30 increase in oil prices resulted in more than $3 billion in additional, unplanned costs to DoD. We have to realize we cant fly planes with solar power or sail ships with batteries; advanced biofuels are critical for both civilian and military aviation and maritime uses.

Private companies have made substantial investments and rapid progress in researching and developing advanced biofuels. Building new advanced biofuel biorefineries requires large capital investments at a time when capital formation has been hampered by the recent economic downturn. Public-private partnerships such as that announced today can help attract the additional private investment needed to complete the job. The Defense Department has used these partnerships many times in the past to ensure that we maintain a domestic capacity to produce materials that are vital to national security.

Ensuring that fuel markets are open to new technologies by maintaining the Renewable Fuel Standard is also a fundamental necessity for the biofuels industry to attract investment and complete the job. Federal leadership and policy stability are necessary to achieving energy security.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech NOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtech NOW.

Upcoming BIO Events

BIO India International Conference September 12 13, 2012 Mumbai, India

Livestock Biotech Summit September 19 21, 2012 Kansas City, MO

Read the original:
BIO Applauds DoD’s Announced Advanced Drop-In Biofuel Production Project

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/tnv4rd/the_chinese_randd) has announced the addition of the "The Chinese R&D Landscape - Biotechnology" report to their offering.

R&D in China in the field of biotechnology has surged over the last decade. This report seeks to answer the following questions related to this surge in R&D:

- Where in China does the R&D in the field of biotechnology take place?

- What companies and academic institutions in China are driving this R&D effort?

- What has been the focus of Chinese R&D in the field of biotechnology?

The foundation for the study has been the complete database of Chinese invention patents and patent applications from the State Intellectual Property Office of China. This database has been supplemented with geographical data, thereby providing information on the who', what', where' and when' of invention in China. Only patents with Chinese priority have been included in the analysis, i.e. not patents filed elsewhere but extended to China.

The Following Information is Included in the Report:

- The top 20 cities with regards to the number of patent applications in the field of biotechnology, along with the number of applications and share of all applications in each city.

- The top 10 companies with regards to the number of patent applications in the field of biotechnology, along with the cities they are located in, number of patent applications, and main patenting area (defined by the main International Patent Classification assigned to their patents).

Read the rest here:
Research and Markets: The Chinese R&D Landscape - Biotechnology

WASHINGTON--(BUSINESS WIRE)--

Biotechnology Industry Organization (BIO)President and CEO Jim Greenwood issued the following statement on the ruling issued today by the U.S. Supreme Court regarding the Affordable Care Act:

BIO will continue to work with relevant federal and state agencies to ensure implementation of the law in a manner that helps enable the U.S. biotech communitys continued development of lifesaving cures and other medical breakthroughs while expanding patient access to these critical cures, medicines and innovations. We will work to ensure that biotech researchers can continue to address the diseases of today while conducting the research and investment required to develop the advanced medicines and cures of tomorrow.

We also will continue our work with U.S. Food and Drug Administration (FDA) to implement the bipartisan-backed biosimilars pathway that was enacted under the law. Specifically, we will advocate for implementation approaches that ensure patient safety, expand patient access and competition, and provide necessary and fair incentives that will help spur continued biomedical breakthroughs. FDA regulations and guidance must help todays patients while enabling the biotech community to move into tomorrow with cures and continued breakthroughs so our children and grandchildren won't have to live with the same diseases we have faced and, perhaps, one day, any diseases at all.

In addition, BIO will continue to support efforts to repeal the Independent Payment Advisory Board (IPAB), which threatens patient access to needed cures and medical breakthroughs.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtechNOW.

Upcoming BIO Events

BIO India International Conference September 12 13, 2012 Mumbai, India

Livestock Biotech Summit September 19 21, 2012 Kansas City, MO

Read this article:
Supreme Court Affordable Care Act Ruling Must Now Lead to Implementation That Will Promote Innovation and Expand ...

Newswise (Washington, D.C., June 29, 2012) In an effort to improve public understanding of modern food production, the International Food Information Council (IFIC) Foundation has released five videos featuring leading physicians in the fields of pediatrics, food allergy and obstetrics who answer frequently asked questions about food biotechnology. To view the videos, click here.

Technology, including food biotechnology, has for many years been an important part of producing safe and affordable food for a growing world population, yet questions about certain aspects of safety and benefits remain, said IFIC Foundation President and CEO David Schmidt. For that reason, we asked leading physicians to respond to a number of common concerns and explain why they are confident in the safety of food produced using biotechnology.

Physicians featured in the videos include:

Wesley Burks, MD, Chairman of the Department of Pediatrics at the University of North Carolina Medical School and Physician in Chief of the North Carolina Childrens Hospital. Dr. Burks currently serves as the president of the American Academy of Allergy, Asthma and Immunology.

Laurie Green, MD, founding partner of the Pacific Womens OB/GYN Medical Group in San Francisco, California. Dr. Green is past president of the California Academy of Medicine and past president of the San Francisco Gynecological Society. She is a member of the Susan G. Komen Foundation Board of Directors.

Ronald Kleinman, MD, Physician in Chief of the Massachusetts General Hospital for Children, Chair of the Department of Pediatrics and Chief of the Pediatric Gastroenterology and Nutrition Unit at Massachusetts General Hospital. Dr. Kleinman also teaches Pediatrics at Harvard Medical School.

Suzanne S. Teuber, MD, professor at the University of California, Davis School of Medicine, specializes in allergy and clinical immunology with a particular interest in food allergies of all types. She is the training program director for the Allergy and Immunology Fellowship Program at UC Davis.

Earlier this month, the American Medical Associations (AMA) House of Delegates reaffirmed its support for the continued use of biotechnology in the production of safe, nutritious food. The AMA recognized the continuing validity of the foundational principles of federal regulation that in all aspects, foods produced though biotechnology present no unique hazards or risks than foods produced by other methods. The AMA also stated that there is no scientific justification for special labeling of bioengineered foods, as a class, and that voluntary labeling is without value unless it is accompanied by focused consumer education. The AMA urged government, industry, consumer advocacy groups, and the scientific and medical communities to educate the public and improve the availability of unbiased information and research activities on bioengineered foods. These IFIC Foundation videos are consistent with that goal.

Results of IFICs latest survey on US consumer attitudes toward food biotechnology and additional resources can be found at the links below.

Additional Resources on Food Biotechnology:

The rest is here:
Physicians Answer Questions About Food Biotechnology in IFIC Foundation Videos

27-06-2012 17:38 Technologies, such as food biotechnology, have become an important part of agriculture. However, many myths and misperceptions about food biotechnology have led to questions about its safety and benefits for the public. The video segments below were developed to help clarify the facts on food produced through biotechnology and to address some of your most common questions. In the videos, physicians who are leaders in their field discuss the following topics as they relate to food biotechnology: Safety; Allergies; Children; Benefits; and Labeling. These physicians have relevant background in these areas, as well as knowledge of the safety and health research around food biotechnology. For more information and more videos from this series, visit: Copyright 2012 International Food Information Council (IFIC) Foundation -- For informational and educational purposes only; not for advertising or other commercial use without written permission from the IFIC Foundation. For more information, please visit: http://www.foodinsight.org.

Read more from the original source:
Children: Are food produced through biotechnology safe for children and pregnant women? - Video

27-06-2012 17:38 Technologies, such as food biotechnology, have become an important part of agriculture. However, many myths and misperceptions about food biotechnology have led to questions about its safety and benefits for the public. The video segments below were developed to help clarify the facts on food produced through biotechnology and to address some of your most common questions. In the videos, physicians who are leaders in their field discuss the following topics as they relate to food biotechnology: Safety; Allergies; Children; Benefits; and Labeling. These physicians have relevant background in these areas, as well as knowledge of the safety and health research around food biotechnology. For more information and more videos from this series, visit: Copyright 2012 International Food Information Council (IFIC) Foundation -- For informational and educational purposes only; not for advertising or other commercial use without written permission from the IFIC Foundation. For more information, please visit: http://www.foodinsight.org.

Follow this link:
Benefits: What are the benefits of biotechnology? - Video

CEDAR KNOLLS, NJ--(Marketwire -06/27/12)- MYOS Corporation (MYOS), a company focused on the discovery, development and commercialization of muscle health and performance therapeutic products, today announced that it has appointed Sol J. Barer, Ph.D., to Chair its Scientific Advisory Board.

Dr. Barer is the former Chairman and Chief Executive Officer of Celgene Corporation, a leading global biotechnology company specializing in cancer, hematologic and immunologic pharmaceuticals. He retired last year from a successful Celgene career where he served as Chairman from 2006 to 2011, and Chief Executive Officer from 2006 to 2010. Prior, he served as Celgene President and Chief Operating Officer since 1993, and 1994, respectively.

Dr. Barer serves as a director of a number of corporate and not-for-profit Boards.

Commenting on his appointment to Chairman of the MYOS Scientific Advisory Board, Dr. Barer said, "The nascent field of muscle biology and the technologies which maximize the health and performance of this organ system represents significant, previously untapped potential. MYOS is positioning itself to play an important and meaningful role in the discovery, development and clinical use of new products which will improve the health and performance of an organ system which we often forget is so vital to the quality of our lives.

"I am especially pleased to serve in this position so early in the Company's development, and to collaborate with its Board and growing management team," he added.

Commenting on Dr. Barer's appointment, Chairman of the MYOS Board of Directors Robert J. Hariri, M.D., Ph.D., said, "It is a special honor to welcome my long time colleague, friend and mentor, Dr. Barer to the Advisory Board. I consider Sol to be one of the visionary leaders who have helped shape the biotechnology industry, and truly value his insight into our sector's science, marketplace and corporate development."

Dr. Hariri serves as chief executive officer of Celgene Cellular Therapeutics, a division of Celgene Corporation, a position he has held since 2005. Prior to joining Celgene Cellular Therapeutics as president in 2002, Dr. Hariri was founder, chairman and chief scientific officer at Anthrogenesis Corporation/LIFEBANK, Inc., a privately held biomedical technology and service corporation involved in human stem cell therapeutics, which was acquired by Celgene in 2002.

About MYOS CorporationMYOS Corporation is a development stage company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance (www.myoscorp.com).

MYOS is the owner of MYO-T12, the world's first clinically demonstrated myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. MYO-T12 is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards of physical health and wellness enhancement. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company," visit http://www.MYOT12.com.

Forward-Looking StatementsAny statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful launch of Myo-X, the ability to generate the forecasted revenue stream and cash flow from sales of Myo-X, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

The rest is here:
MYOS Names Veteran Biotechnology Executive Dr. Sol J. Barer to Chair Scientific Advisory Board

TAIPEI, June 25, 2012 /PRNewswire-Asia/ -- TaiGen Biotechnology Company, Limited ("TaiGen") and Zhejiang Medicine Company, Limited ("ZMC") today announced that they have signed an exclusive agreement to manufacture and commercialize nemonoxacin, a novel broad-spectrum antibiotic, in China (excluding Hong Kong, and Macau). Nemonoxacin is a novel broad-spectrum non-fluorinated quinolone antibiotic under development for respiratory infections. TaiGen will be responsible for completing the Phase 3 clinical trial for community acquired pneumonia ("CAP") in China. ZMC will be responsible for manufacturing, sales and marketing of nemonoxacin in China through its wholly-owned subsidiary, XinChang Pharmaceuticals. TaiGen will retain full development and commercialization rights outside the licensed territory including Taiwan, the United States, European Union, and Japan. Under the terms of the agreement, TaiGen will receive an upfront payment of US$ 8 million from ZMC and will receive additional milestones as well as royalties on product sales. The term of the agreement is 20 years.

Nemonoxacin has demonstrated efficacy and safety in CAP and diabetic foot infection in multinational and multi-center clinical trials conducted by TaiGen. In particular, nemonoxacin has excellent activity against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant MRSA. Nemonoxacin is taken once-a-day and available in both oral and intravenous formulations. Currently, TaiGen is completing a Phase 3 CAP trial with more than 500 patients from Taiwan and mainland China and expects to file new drug applications in Taiwan and mainland China simultaneously in early 2013.

China is one of the major antibiotic markets in the world. According to IMS, the sales of antibiotics in 2011 were approximately US$ 11 billion (RMB 68 billion) and account for almost 20% of the total pharmaceuticals sales. Rate of antibiotic resistant infections in China is among the highest in the world.

Mr. Li Chun Bo, Chairman of the ZMC, commented, "We are impressed with nemonoxacin's broad spectrum activity towards drug-resistant bacteria, in particular, MRSA, and excellent safety profile. We are excited to establish this partnership with TaiGen because of its reputation as a premier research-based biotech company in Asia. This partnership will break new ground for cross-strait collaboration in the pharmaceutical industry. Nemonoxacin will be a major addition to ZMC's antibiotic product line and significant profit driver".

Dr. Ming-Chu Hsu, President and Chief Executive Officer of TaiGen, said, "China is the world's fastest growing pharmaceutical market. It is poised to overtake Japan as the second largest pharmaceutical market. We are extremely please to establish our nemonoxacin partnership with ZMC, a first-class pharmaceutical company and major player in the Chinese antibiotics market. With nemonoxacin, TaiGen and ZMC together will bring new medicine to treat unmet medical needs in China. This partnership will not only set a new record for pharmaceutical licensing involving a Taiwanese and a mainland Chinese company but hopefully will also become a model of the future collaborations," Dr. Hsu also added, "With the conclusion of the partnership in China, we will actively pursue nemonoxacin licensing discussions in other territories such as European Union."

About Zhejiang Medicine

Zhejiang Medicine Company, Limited is a leading pharmaceutical company in China specializing in sales and distribution of pharmaceuticals and manufacturing of active pharmaceutical ingredients (vitamins and antibiotics). Its sales revenue in 2011 is US $740 million (RMB 4.8 billion). ZMC is a leader in the Chinese antibiotic market with levofloxacin, vancomycin, and teicoplanin in the product line. ZMC's Lai Li Xin, a branded levofloxacin, is one of the top selling antibiotics in China with 2011 sales exceeding US $110 million (RMB 735 million). In addition to pharmaceuticals sales, ZMC is also known for its manufacturing quality. Its vancomycin active pharmaceutical ingredient has obtained GMP qualification from US Food and Drug Administration (FDA) and exported to western countries. ZMC is publicly listed in the Shanghai Stock Exchange (600216) and has a market capitalization of RMB 11 billion.

About TaiGen Biotechnology

TaiGen Biotechnology is a leading research-based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, mainland China. TaiGen has full discovery research capacity in Taiwan and clinical development in mainland China/Taiwan/US. In addition to nemonoxacin, TaiGen has two other in-house discovered new chemical entities in clinical development under IND with US FDA: TG-0054, a chemokine receptor antagonist for stem cell transplantation and chemosensitization, in Phase 2 and TG-2349, a HCV protease inhibitor for treatment of chronic hepatitis infection, in Phase 1. Both TG-0054 and TG-2349 are currently in clinical development in the US.

Disclaimer

See the original post here:
TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine

25 June 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Medicines (Xetra: 938858 - news) and Healthcare products Regulatory Agency (MHRA) inspection

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce that the inspection in early June of our Cramlington site, by the MHRA, was completed successfully. The inspector spent three days at our facility and raised no critical or major observations. Critical and/or major observations is the terminology used by the inspector to define shortcomings that usually require remedial action before a license can be granted. The first inspection of what is effectively a new facility is the most challenging and it is a credit to the Angel team that Cramlington met the standard required to be added to Angel's GMP (KOSDAQ: 018290.KQ - news) license.

Dr Paul Harper, ABH Chairman said: "This is a significant achievement for the company and opens the way to expand our business by being able to offer GMP capacity suitable to accommodate larger programmes. This has been achieved whilst maintaining our existing business activities and undertaking the integration of Angel Biomedical Ltd as a new Group company. The Board of Directors wish to commend the team for an exemplary performance."

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Acting CEO/Commercial Director http://www.angelbio.com

Read more:
Angel Biotechnology - Successful Completion of MHRA Inspection

WASHINGTON--(BUSINESS WIRE)--

Biotechnology Industry Organization (BIO)President and CEO Jim Greenwood released the following statement on passage of S. 3187, the Food and Drug Administration Safety and Innovation Act (FDASIA), by the U.S. Senate:

We are pleased that Congress was able to move quickly to consider, pass, and send this legislation to the President for his signature well in advance of the expiration of the Prescription Drug User Fee Act (PDUFA IV) at the end of September.

We appreciate the leadership of Senate Health, Education, Labor and Pensions Committee Chair Tom Harkin (D-IA) and Ranking Member Mike Enzi (R-WY) as well as of House Energy and Commerce Committee Chair Fred Upton (R-MI) and Ranking Member Henry Waxman (D-CA) for securing approval in both Chambers.

FDASIA reflects enhancements to PDUFA that were widely and strongly supported by stakeholders. The legislation will enhance the development and review of innovative new therapies through increased transparency and scientific dialogue, advancements in regulatory science and strengthened post-market review. It will also increase the Food and Drug Administrations (FDA) access to external expertise to improve the drug review process.

"FDASIA will foster timely interactive communication with sponsors during the drug development phase as a core Agency activity to facilitate the conduct of efficient and effective drug development programs and help make safe and effective medicines available to Americans in a timely manner.

Further, the enhanced Accelerated Approval pathway will help expedite the development of modern, targeted, and personalized therapies for patients suffering from serious and life-threatening diseases while preserving the FDAs robust standards for safety and effectiveness.

The inclusion of the permanent reauthorization of the Best Pharmaceuticals for Children Act and Pediatric Research Equity Act in FDASIA will encourage continued investment in pediatric research and help ensure that new drugs and biologics can be used safely and appropriately in pediatric patients.

BIO looks forward to working with the FDA on the implementation of FDASIA, and we will continue to work with Congress on the creation of a uniform national standard for pharmaceutical product traceability to preserve patient access to safe medicines.

About BIO

Continued here:
BIO Commends Senate for Approval of User Fee Package

June 22, 2012 - BIO congratulated member companies Elevance Renewable Sciences, Inc. and Codexis, Inc. on receiving 2012 Presidential Green Chemistry Challenge Awards for pioneering advances in applying industrial biotechnology to manufacturing. Elevance Renewable Sciences received Small Business Award for producing high-performing, renewable specialty chemicals at advantageous costs, while Codexis received Greener Synthetic Pathways Award for efficient biocatalytic process to manufacture simvastatin. Biotechnology Industry Organization 1201 Maryland Ave., SW, Ste. 900 Washington, DC, 20024 USA Press release date: June 18, 2012

WASHINGTON-- Industrial biotechnology is being used to improve production of cleaner, healthier products, saving energy, reducing costs, and reducing pollution from manufacturing. The Biotechnology Industry Organization (BIO) today congratulated member companies Elevance Renewable Sciences and Codexis on receiving 2012 Presidential Green Chemistry Challenge Awards.

"Industrial biotechnology is already being used to produce products for the home that are cleaner and safer for the environment, require less energy for manufacturing and lower production costs"

"Industrial biotechnology is already being used to produce products for the home that are cleaner and safer for the environment, require less energy for manufacturing and lower production costs," said Brent Erickson, executive vice president of BIO's Industrial & Environmental Section. "BIO congratulates our members who have been recognized through the Presidential Green Chemistry Awards for their pioneering advances in applying industrial biotechnology to manufacturing. Their achievements show that more widespread adoption of industrial biotechnology processes can help establish a new path for sustainable economic growth and job creation, without continued reliance on foreign oil."

Elevance Renewable Sciences, Inc. received a Small Business Award for producing high-performing, renewable specialty chemicals at advantageous costs. Elevance employs Nobel-prize-winning catalyst technology to produce novel, high-performance renewable specialty chemicals for many uses that combine the benefits of both petrochemicals and biobased chemicals. The technology consumes significantly less energy and reduces greenhouse gas emissions by 50 percent compared to petrochemical technologies.

Codexis, Inc. received a Greener Synthetic Pathways Award for an efficient biocatalytic process to manufacture simvastatin, a leading drug for treating high cholesterol. The previous multistep method for producing simvastatin was wasteful and used large amounts of hazardous reagents. Codexis optimized the chemical process to greatly reduce hazard and waste, be more cost-effective and meet the needs of customers.

About BIO BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech NOW, an online portal and monthly newsletter chronicling "innovations transforming our world." Subscribe to BIOtech NOW.

Contacts BIO Paul Winters, 202-962-9237 pwinters@bio.org

Industrial Specialties Mfg performs a unique role. If what we offer isn't exactly what you need, we'll design something that is. We'll provide special products at volume levels where others won't. Also check out our 150,000 standard fittings.

Visit our website

Read the original here:
Industrial Biotechnology Companies Receive Green Chemistry Awards for Cleaner, Safer ...

Area Students Learn To Analyze DNA at Bowie State University

Bowie, Md. Area college and high school students are using their knowledge of science and technology in hands-on research experiments at the Biotechnology Summer Institute at Bowie State University (BSU).

It brings everything together that weve done over these last three years and puts it into practice, said Tamara Quill, of College Park, Maryland, a rising senior at Bowie State University, as she worked with a fellow student to analyze a DNA sample in a state-of-the-art laboratory. Being a biology major, a lot of times you just take in so much information, but you really dont know the practical side of it. This actually gives you an insight into the practical side.

The Biotechnology Summer Institute is designed to provide interactive research experiences to undergraduate and high school students interested in the disciplines of science, technology, engineering, and mathematics. Students from Bowie State University, as well as other area colleges and high schools including: Morgan State University, University of Maryland College Park, Anne Arundel Community College and Largo High School have participated in the program since June 4, 2012. The students have spent hours in lectures and lab classes, learning such skills as forensic fingerprinting and DNA extraction. Later this month, area high school teachers will have the opportunity to learn how to educate youth in the biotechnology industry, as part of the institute.

The goals of the Biotechnology Summer Institute are to promote the interest of students in biotechnology as an alternative career path, provide research experience for students to succeed in postgraduate education, and train personnel to serve in the burgeoning biotechnology industry in Maryland and the nation, said Dr. George Ude, associate professor in the Department of Natural Sciences at Bowie State University, who is coordinating the institute. The institute also impacts high school students by providing teachers additional skills in biotechnology to increase their capacity to prepare students to succeed in college, Dr. Ude said.

Quill has enjoyed her experience so far and said it has given her a wider understanding of what careers are available within the biology field. You could just read about it, but to get that hands-on experience, you cant beat that, she said.

For Kany Dieye, a 2012 Bowie State University graduate from Bowie, Md., the institute has also broadened her perspective of what careers are possible for her. While she has always had an interest in how biology and technology work together, the institute has allowed her to experience how these disciplines can be applied in real-world contexts.

Last week, for example, one laboratory exercise focused on DNA profiling and its application in investigating criminal evidence and in solving medical dilemmas, such as in paternity testing.

I love doing research, and thats what were doing with the experiments in knowing how to do all the processes and procedures when it comes to biology and the health field. We get to run experiments from the beginning to the result youre pretty much doing all the steps as a student, said Dieye, who plans to pursue a masters degree in bioinformatics. It will help me with what I want to do in the future in the health field.

The institute ran until June 15 for undergraduate and high school students and from June 18-29 for high school teachers. Along with Dr. Ude, Dr. Gary Coleman, Department of Plant Sciences and Landscape Architecture; Dr. Ganesh Sriram, Department of Chemical and Biomolecular Engineering; and Dr. Jianhua Zhu, Department of Plant Sciences and Landscape Architecture all from the University of Maryland are also instructors for the institute

Read the original post:
Biotechnology Summer Institute helps students practice new skills

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) today applauded Senate Leaders Harry Reid (D-Nev.) and Mitch McConnell (R-Ky.) along with Senate Agriculture Committee Leaders Debbie Stabenow (D-Mich.) and Pat Roberts (R-Kans.) and other Senators for reauthorizing the Farm Bill, including a strong Energy Title with mandatory funding for vital renewable energy programs.

Brent Erickson, executive vice president of BIOs Industrial & Environmental Section, stated, Farm Bill energy programs play an essential role in helping new companies unlock private investment capital for construction of innovative biorefineries; putting underutilized farmland back into production of next-generation energy crops; and revitalizing rural America. These programs can continue to provide a high rate of return to America by supporting the emergence of new agricultural markets and innovative industries, such as renewable chemicals. The programs have already supported construction of a number of new biorefineries in every region of the United States, creating new employment opportunities and economic revitalization of rural areas.

BIO applauds the bipartisan cooperation that brought this legislation to successful passage. We urge leaders of the House of Representatives to take up this important legislation.

For more information, see the BIO factsheet Farm Bill Energy Title: Timeline of a Successful Policy Initiative.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech NOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtech NOW.

Upcoming BIO Events

BIO India International Conference September 12 13, 2012 Mumbai, India

Livestock Biotech Summit September 19 21, 2012 Kansas City, MO

See the original post here:
BIO Applauds Senate Reauthorization of Farm Bill

June 21, 2012 - According to "Biotechnology: Bringing Innovation to Neglected Disease Research and Development," small- to medium-sized biotech companies bring innovation to global health. Findings show that 134 biotechnology companies are participating in neglected disease research and development, which represents participation in 39% of 191 new drugs, vaccines, and diagnostics in development. Report also finds that 64% of all products in development by biotech companies involve partnering. Biotechnology Industry Organization 1201 Maryland Ave., SW, Ste. 900 Washington, DC, 20024 USA Press release date: June 18, 2012

The new report will be released today at the 2012 BIO International Convention in Boston, Mass.

2012 BIO International Convention 2012 BIO International Convention:Biotechnology Industry Organization WASHINGTON--Small- to medium-sized biotechnology companies are bringing innovation to global health, according to a report published today by BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO). The report shows that 134 biotechnology companies are participating in neglected disease research and development, which represents participation in 39% of the 191 new drugs, vaccines, and diagnostics in development for neglected diseases such as malaria, tuberculosis, dengue fever, and others.

"It is encouraging that small- to medium-sized biotechnology companies that lead the charge in developing life-saving medicines and technologies in the developed world are so engaged in creating new drugs, vaccines, and diagnostics for the neglected diseases primarily affecting the poor in the developing world"

Partnering is an important driver for today's biotechnology companies. The new report, Biotechnology: Bringing Innovation to Neglected Disease Research and Development, finds that 64% of all products in development by biotechnology companies across the pipeline of drugs, vaccines, and diagnostics for neglected diseases involve partnering.

According to the report, product development partnerships (PDPs) - a unique public-private partnering mechanism created to increase biopharmaceutical participation in neglected disease R&D, government agencies, and academic institutions - are driving this biotechnology company partnering for neglected diseases. Although PDPs are the focal point of industry engagement in global health, they are the second most frequent partner to biotechnology companies after academia with involvement in 52% of partnered projects. When a PDP is not involved in a project, biotechnology partnerships with government agencies increase, especially for vaccines and diagnostics.

Across all neglected diseases, biotechnology companies work alone 36% of the time, according to the report. For tuberculosis and dengue fever, companies more frequently overcome barriers and leverage some market potential to work alone. This may be because small to medium-sized companies perceive a potential market opportunity.

"We were very pleased to see the level of the biotechnology sector's engagement in global health research and development, as a critical source of innovation. To continue progress in addressing the unmet medical needs of the developing world, both biotechnology companies and global health groups should ramp up commitment and involvement," says Don Joseph, CEO of BVGH. "Our new report provides specific recommendations both to biotechnology companies and neglected disease stakeholders from academia, governments, nonprofits, and foundations to increase and improve their collaborative work in neglected disease research. Accelerating solutions for these devastating diseases presents major challenges but can happen if these groups continue and increase their work together."

While the report finds that small to medium-sized biotechnology companies are involved in 39% of all projects for neglected disease, BIO estimates there are nearly 3,000 public and private biotechnology companies worldwide. At least 90% of these companies focus on health research and development, suggesting that the 134 biotechnology companies participating in neglected disease research and development identified in the report represent about 5% of global biotechnology companies.

"It is encouraging that small- to medium-sized biotechnology companies that lead the charge in developing life-saving medicines and technologies in the developed world are so engaged in creating new drugs, vaccines, and diagnostics for the neglected diseases primarily affecting the poor in the developing world," says Jim Greenwood, President and CEO of BIO. "The true value of this week's BIO International Convention is to bring together industry leaders who can share insights and engage in discussions focused on potential collaborations that could lead to scientific breakthroughs that will address these and other global challenges."

Continue reading here:
New Report Finds Biotechnology Companies are Participating in 39% of All Projects in ...

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/c3966c/biotechnology_in_b) has announced the addition of Smithers Information Ltd's new book "Biotechnology in Biopolymers" to their offering.

This comprehensive book provides up-to-date information on the developments in the field of biopolymers. Close attention has been paid to include all the important aspects that are necessary to understand the field. The book introduces the reader with the progress in the field, followed by outlining its applications in different areas. Different methods and techniques of synthesis and characterization are detailed as individual chapters. Various mode and mechanism of degradation of materials will be discussed. There is a dedicated chapter on industrially available biopolymers and their applications and well as a chapter detailing the ongoing research, current trends and future challenges.

Unlike other books, this book consists of information that is useful for students who are interested in biotech and polymer research. Each chapter will explain the science and technology from the inception to advance state of the art available to date. This book will also be useful for the researcher involved in the high-tech research as it will provide them the up-to-date information available in this field.

Key Topics Covered:

1 Biopolymers: An Indispensable Tool for Biotechnology

2 Spectroscopic Analysis of Biopolymers

3 Thermal Analysis of Biopolymer Materials for High-performance Applications

4 Mechanical Properties of Biopolymers

5 Natural Fibres and Their Use in the Production of Biocomposites

Continue reading here:
Research and Markets: Biotechnology in Biopolymers

BOSTON--(BUSINESS WIRE)--

The Biotechnology Institute announces today the formation of the nationally coordinated effort of state bioscience organizations. This effort the Coalition of State Bioscience Institutes (CSBI) - ensures Americas leadership in bioscience innovation by delivering industry-led life science education, workforce development and entrepreneurship programs across the county. The Biotech Institute is a founding member of CSBI and serves as its administrative organization. The formation of CSBI was announced at the 2012 BIO International Convention, the industrys global event for biotechnology that is hosted by the Biotechnology Industry Organization (BIO).

By convening the countrys state bioscience programs through this Coalition, we are able to serve as the conduit betweenlearning institutions and life science companies, said Janelle Curtis, Biotechnology Institute VP for Programs. As the countrys national organization dedicated to bioscience education, the Institute looks forward to working with this group toward our common goal to support innovation in the life sciences.

CSBI is leveraging resources across the United States to speak with a united voice for the biotech industry on life science education, workforce development and entrepreneurship, said CSBI acting co-chair Lance Hartford, executive director, MassBioEd. We focus on programs that the life science industry is uniquely positioned to deliver and can be replicated across many states and scaled-up nationally.

Currently, CSBI is identifying leading state programs for national consideration. These programs include teacher-training initiatives such as iBIO Institutes TalentSparks!; workforce competitiveness programs including Oregon Bioscience Associations BioPro and BIOCOM Institutes BioCollaborative; and BayBio Institutes Expert Network resource for entrepreneurs. CSBI is also designing a web-based clearinghouse of all current state-level programs focused on life science education, workforce training and entrepreneurship.

Working together since December 2011, CSBI serves as an umbrella for standard practice sharing, joint fundraising and national initiatives for life science (STEM) education (student education, career exploration and teacher professional development); workforce development (workforce training, incumbent worker professional development, dislocated worker training); and entrepreneurship. CSBI provides the opportunity for state bioscience organizations to share knowledge with the goal of improving bioscience education and innovation, while maximizing industry support. With its focus in these areas, the CSBI complements the life science policy work of the Council of State Bioscience Associations (CSBA), formed by BIO in 2002.

CSBI founding organizations include BayBio Institute, BIOCOM Institute, the Biotechnology Institute, iBIO Institute, KansasBio, MassBioEd, MdBio Foundation and the Oregon Bioscience Association. Forty-one state bioscience organizations are CSBI members with nine additional groups expected to join. The Coalition is co-chaired by BayBio Institute executive director Lori Lindburg and MassBioEd executive director Lance Hartford. The Biotechnology Institute serves as CSBIs administrative organization. By partnering, CSBI members bring unprecedented access to programs, facilitate national communication, and connect an extensive network of industry professionals. CSBI is supported with funding provided by Human Genome Sciences.

ABOUT THE BIOTECHNOLOGY INSTITUTE

The Biotechnology Institute is an independent, national nonprofit organization dedicated to education about the present and future impact of biotechnology. Its mission is to engage, excite and educate the public, particularly students and teachers, about biotechnology and its immense potential for solving human health, food and environmental problems. For more information, visit http://www.biotechinstitute.org.

ABOUT THE BIO INTERNATIONAL CONVENTION

Go here to see the original:
Biotechnology Institute Leads Effort to Bring Life Science Education, Workforce Training and Entrepreneurship to the ...

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) unveiled a report on the role of intellectual property rights in encouraging upstream research and development as well as downstream commercialization of biotechnology at the 2012 BIO International Convention.

This report is further proof of the positive impact of intellectual property rights in both established and emerging economies, and will be a useful tool as we work with the many countries seeking to grow the biotechnology industry, stated Joseph Damond, BIO Senior Vice President of International Affairs. We felt it was important to provide empirical evidence and case studies for a more informed discussion on the role of intellectual property in global economic development and in commercializing innovative products for patients and other consumers.

The report outlines how intellectual property rights and technology transfer mechanisms encourage collaboration and lead to the research and development of new biotechnologies, particularly in emerging and developing economies.

The report, titled Taking Stock: How Global Biotechnology Benefits from Intellectual Property Rights, found that:

There is a growing body of evidence suggesting a positive link between economic development and growth, technology transfer, increased rates of innovation and the strengthening of intellectual property rights. This is particularly promising in certain knowledge-intensive sectors, such as biopharmaceuticals, said Meir Pugatch, Managing Director and Founder of the Pugatch Consilium.

The report was authored by Meir Perez Pugatch, David Torstensson and Rachel Chu of the Pugatch Consilium and is available at http://www.bio.org/sites/default/files/Pugatch%20Consilium%20-%20Taking%20Stock%20Final%20Report%20%282%29.pdf.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtechNOW.

Upcoming BIO Events

Original post:
Intellectual Property Encourages Collaboration, R&D in Developing Economies

BOSTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) today unveiled several new opinion surveys at the 2012 BIO International Convention, taking place this week in Boston. The surveys - conducted by the bipartisan pairing of Public Opinion Strategies and Hart Research Associates - found:

"These survey results are clear: The American people want policymakers to support cutting-edge research that will enable biotechnology to fulfill its potential to heal, fuel and feed the world, said Jim Greenwood, President and CEO of BIO. We are at a critical crossroads. We need policies in place that support investment in biotech innovation and a more streamlined regulatory process that properly protects patient safety and speeds the delivery of breakthrough medicines and cures to sick patients or we risk losing Americas leadership in biotech innovation.

The research included a survey of national voter attitudes, a survey of biotechnology executives and a third survey examining the attitudes of those attending the 2012 BIO International Convention.

Biotechnology Executives Concerned About Regulatory Burdens, Less Optimistic

The survey of executives at BIO members companies found these industry leaders believe government regulation has had a negative impact on the biotech industry and this is largely unchanged compared to a survey conducted on behalf of BIO five years ago (58 percent today vs. 56 percent in 2007). They are less optimistic today than they were in 2007 (63 percent compared to 79 percent) that, in the future, the biotechnology industry will continue to develop new therapeutics and products to help address global needs in healthcare, agriculture, energy and the environment.

When compared to BIOs 2007 survey, todays industry executives reported the following:

Other key findings in the research include:

Methodology

The national surveys of N=169 BIO member company executives and of N=800 registered voters were conducted May 14-24 and May 20-23, 2012, respectively, by Public Opinion Strategies and Peter D. Hart Research Associates on behalf of the Biotechnology Industry Organization.

Link:
Americans and Biotechnology Executives Remain Optimistic About Future of Biotechnology Despite Serious Industry ...